Low Libido on TRT? A Bloodwork-First Troubleshooting Guide

Your testosterone is optimized. Your E2 is dialled in. So why is your libido still dead?

This is one of the most frustrating experiences in TRT. Everything on paper looks right. Your clinic is happy with your labs. But your sex drive is absent, your erections are unreliable, and you feel like something is fundamentally broken.

The problem is that most TRT management stops at total testosterone. That is necessary but not sufficient. Libido is not a single-hormone problem. It runs across three distinct layers: the hormonal environment (free testosterone, estradiol, prolactin, thyroid, DHT, cortisol), the pharmacological tools available when hormones alone fall short, and the dopaminergic and psychological factors that no amount of testosterone can override.

Work through all three layers in order and you will either find the answer or narrow it down to the one thing that actually needs fixing.

Why testosterone alone does not guarantee libido

The conventional model is wrong. It goes: low testosterone causes low libido, therefore testosterone replacement fixes low libido. This is true enough to be useful in practice, but it obscures what is actually happening.

Libido is primarily a dopaminergic phenomenon, not just a hormonal one. Sexual desire originates in the mesolimbic reward system. Testosterone sensitises this system to sexual stimuli, but it does not generate desire by itself. The TRAVERSE trial enrolled 5,246 men overall; the nested sexual function study included 1,161 men over a median 22 months. Testosterone therapy significantly improved sexual desire compared to placebo. But it did not improve erectile function scores (Pencina et al., 2024). Testosterone improved wanting. It did not reliably fix the mechanics of erections.

This distinction matters enormously for troubleshooting. Absent desire and poor erectile function are different problems with partially different solutions, and conflating them leads to months of chasing the wrong marker.

The three-layer model is practical:

1. The hormonal layer: the biochemical environment that makes desire and function possible.
2. The pharmacological layer: targeted tools for mechanics (tadalafil) and desire (PT-141) when hormones are already optimized.
3. The dopamine and psychology layer: reward circuit conditioning, performance anxiety, sleep disorders, and relationship factors that no drug addresses.

Work through these in sequence. Layer 1 first, always. There is no point adding PT-141 to a protocol where your prolactin is 35 ng/mL.

Layer 1: the hormonal panel that actually matters

Free testosterone and SHBG: the number your clinic ignores

Total testosterone is almost useless for diagnosing libido problems in men already on TRT. The marker that matters is free testosterone: the fraction not bound to SHBG or albumin, and therefore available to enter cells and activate androgen receptors.

The data here is unambiguous. Antonio et al. (2016) studied 3,334 community-dwelling men aged 40-79 and found that men with normal total testosterone but low calculated free testosterone below 220 pmol/L (approximately 63 pg/mL) still had significantly higher rates of sexual dysfunction compared to men with adequate free T (Antonio et al., 2016). Normal total T with low free T is not a normal hormonal state. It is functional hypogonadism.

The culprit is almost always SHBG. Sex hormone-binding globulin binds testosterone with high affinity, effectively removing it from circulation. SHBG rises with ageing (the reason testosterone needs tend to increase over time even on fixed protocols), hypothyroidism (excess TSH stimulates SHBG production in the liver), liver disease (cirrhosis, fatty liver, alcohol use), caloric restriction and very low carbohydrate intake, and certain medications, particularly anticonvulsants.

On your labs, check free testosterone directly or calculate it from total T, SHBG, and albumin using the Vermeulen formula. If free T is below the lower end of the reference range despite a total T in the mid-to-upper normal range, your SHBG is the problem. Addressing the root cause (thyroid, liver, dietary patterns) is preferable to dose escalation.

When to test: always draw blood at trough, 24-48 hours after your last injection, before the next dose. See Blood Test Timing on TRT for the full protocol.

Estradiol: the sweet spot nobody agrees on

Estradiol's role in male libido is more complex than the TRT community usually acknowledges. It is not simply "keep it low and you'll feel better." The relationship is non-linear, and both extremes impair function.

The landmark evidence comes from Finkelstein et al. (2013), who suppressed endogenous testosterone and estradiol in 198 men using goserelin (a GnRH agonist), then added back testosterone and/or estradiol in varying doses. The result: estradiol deficiency independently reduced sexual desire even when testosterone was maintained (Finkelstein et al., 2013). Low E2 kills libido. This is not theoretical.

The upper end has also been quantified. Belladelli et al. (2024) found that estradiol above 42.6 pg/mL was associated with a 2.44-fold increased odds of severe erectile dysfunction (Belladelli et al., 2024). So high E2 worsens function too.

The clinical consensus from these two data points: 20-30 pg/mL on a sensitive assay (LC-MS/MS, not immunoassay) is the zone where libido is best supported. Below 20 pg/mL and you will lose sexual desire regardless of your testosterone level. Above 40-45 pg/mL and erectile quality starts degrading.

One qualifier matters here: use the sensitive assay. Standard immunoassay E2 tests are calibrated for women's ranges and are unreliable below 50 pg/mL in men. Order the sensitive estradiol test specifically. If your lab does not offer it, find one that does.

The practical implication: if your E2 is below 20 on a sensitive assay and your libido is absent, the fix is not more testosterone. The fix is less aromatase inhibitor, a lower anastrozole dose, or switching injection frequency to allow more aromatisation. If E2 is above 45, gentle dose reduction or a low-dose AI is warranted, but use the minimum effective dose. Crashing E2 is worse than running it slightly high. For a full guide to E2 management, see Estradiol on TRT.

Prolactin: the silent killer above 15 ng/mL

Elevated prolactin is probably the most under-checked cause of TRT-era libido loss, and it is easy to miss because most clinics do not routinely test it.

The mechanism is direct: prolactin suppresses GnRH pulsatility at the hypothalamus, which in turn reduces LH and FSH output. More importantly for men already on TRT (who have no endogenous LH anyway), prolactin has direct inhibitory effects on dopaminergic neurons in the mesolimbic system. It blunts the reward response to sexual stimuli at a neurological level.

Falaschi et al. (1978) demonstrated this clearly: when metoclopramide was used to raise prolactin in 5 healthy men with normal testosterone, 4 of 5 lost libido and 3 lost spontaneous erections (Falaschi et al., 1978). Testosterone did not change; prolactin alone was the variable. De Rosa et al. (2004) later showed the reverse: 6 months of cabergoline therapy normalized sexual potency in 60.6% of hyperprolactinemic men (De Rosa et al., 2004). A more recent analysis by Cheng et al. (2025) confirmed that symptomatic hyperprolactinemia (low libido, poor erections) can occur even when testosterone remains in the normal range (Cheng et al., 2025).

The clinical threshold where symptoms appear is not the lab reference range. Reference ranges go up to 15-20 ng/mL, but many men start experiencing libido suppression above 15 ng/mL. Consider anything above 15 ng/mL a flag worth investigating if libido is your complaint.

The two most common causes of elevated prolactin on TRT protocols are 19-nor compounds and pituitary microadenomas. Nandrolone and trenbolone both activate progesterone receptors, which stimulate prolactin release from the pituitary. If you use either compound and your libido is poor, test prolactin before doing anything else. If prolactin is elevated and you are not using 19-nors, order an MRI to rule out a pituitary adenoma.

Thyroid: the overlooked connection

The thyroid-libido link is underappreciated and well-documented.

Carani et al. (2005) examined sexual function in 14 hypothyroid men and found that 64.3% had hypoactive sexual desire disorder. After levothyroxine treatment brought thyroid function to normal, sexual dysfunction improved substantially (Carani et al., 2005). A comprehensive review by Gabrielson et al. (2019) confirmed the bidirectional relationship: both hypothyroidism and hyperthyroidism impair sexual function, with hypothyroidism being more common in the TRT demographic (Gabrielson et al., 2019).

The mechanism involves two pathways. First, hypothyroidism directly reduces dopaminergic tone, which suppresses sexual motivation through the same reward circuit that testosterone sensitises. Second, elevated TSH stimulates SHBG production in the liver. This is the double hit: low thyroid function simultaneously reduces dopaminergic drive and raises SHBG, which lowers free testosterone. You lose twice.

On your panel, do not stop at TSH. A normal TSH with low free T3 (below the bottom third of the reference range) is consistent with subclinical hypothyroidism that will blunt your libido and raise your SHBG. Test TSH, free T3, and free T4 together. For the full picture on thyroid function in the enhanced athlete context, see Thyroid Function on Steroids.

DHT: the androgen that drives desire

Dihydrotestosterone is the most potent androgen in the body, and it plays a specific role in sexual desire that testosterone alone cannot replicate.

Sartorius et al. (2014) administered exogenous DHT to 114 healthy older men for 24 months. DHT suppressed endogenous estradiol via negative feedback, yet 32 of 33 measures of sexual function and mood were maintained, with only a mild, reversible decrease in overall desire (Sartorius et al., 2014). The conclusion: aromatization to estradiol plays only a minimal role in maintaining male sexual function, and androgens have E2-independent effects on libido mediated through DHT specifically.

The practical implication appears when men use 5-alpha reductase inhibitors. Finasteride and dutasteride block the conversion of testosterone to DHT. Traish et al. (2014) documented the extensive sexual side effects of 5-ARIs including persistent low libido, erectile dysfunction, and ejaculatory disorders, which in a subset of men (post-finasteride syndrome) persist long after stopping the drug (Traish et al., 2014). If you are using finasteride or dutasteride for hair loss, your DHT may be suppressed enough to impair libido regardless of your testosterone level. See TRT and Hair Loss: DHT Guide for a full review of this trade-off.

DHT is not routinely tested and the reference range is broad, but if you use a 5-ARI and have low libido, the mechanism is clear. Consider stopping the 5-ARI and switching to a topical approach if hair loss is the concern.

Cortisol: when stress overrides everything

The final hormonal factor is also the one most influenced by lifestyle and the hardest to fix with a drug.

Cumming et al. (1983) demonstrated that acute cortisol elevation directly suppresses testosterone production at the level of the Leydig cells (Cumming et al., 1983). On TRT, exogenous testosterone overrides this suppression at the gonadal level, but cortisol still acts centrally. Chronically elevated cortisol downregulates androgen receptors, which means your tissues become less responsive to whatever testosterone is circulating. It also raises SHBG and competes with androgens for receptor binding.

The practical lesson: if you are under severe psychological or physical stress (caloric deficit, overtraining, high-pressure work, relationship problems), your cortisol is working against your TRT. No dose adjustment fixes a cortisol problem.

Test a morning cortisol (drawn 8-9 AM, at trough for most people) and check where it sits. Values below 15 mcg/dL in the morning suggest HPA axis suppression, often from exogenous steroid use. Values consistently above 25-30 mcg/dL suggest chronic stress activation. Both impair androgen receptor sensitivity.

Layer 2: pharmacological tools beyond testosterone

Once you have confirmed that your hormonal panel is as optimized as it can be (free T adequate, E2 in range, prolactin below 15, thyroid normal, no 5-ARI suppressing DHT), and libido is still impaired, you have two distinct problems to address: desire and mechanics. They require different tools.

Tadalafil 5 mg daily: mechanics, not desire

Tadalafil is a PDE5 inhibitor that works by increasing nitric oxide-mediated vasodilation in penile smooth muscle. It improves erectile function mechanically. It does not generate sexual desire.

The integrated analysis by Porst et al. (2014), pooling 1,913 men across six trials, found that 5 mg daily tadalafil improved IIEF Erectile Function domain scores by 5.4 points compared to placebo (Porst et al., 2014). The 5 mg daily dosing (versus on-demand 10-20 mg) provides consistent erectile readiness without planning around a dose, which improves spontaneity and reduces performance pressure.

There are cardiovascular benefits independent of erectile function. Rosano et al. (2005) demonstrated that tadalafil improved endothelial function in men with increased cardiovascular risk, increasing flow-mediated dilation from 4.2% to 9.3% (Rosano et al., 2005). For men on TRT, who typically carry some degree of cardiovascular risk, that is a genuine secondary benefit.

One critical point: Buvat et al. (2011) found that among hypogonadal men with testosterone at or below 3 ng/mL (300 ng/dL), adding testosterone therapy to tadalafil provided additional benefit beyond the PDE5 inhibitor alone (Buvat et al., 2011). Below that threshold, the nitric oxide signalling pathway is impaired and tadalafil alone is less effective. This is another reason to sort your hormonal layer before relying solely on PDE5 inhibitors.

Tadalafil will not fix absent desire. If you have no interest in sex, tadalafil gives you a better erection during the times you do engage, but it cannot create desire where there is none. That is PT-141's job.

PT-141 (bremelanotide): central desire, not just erections

PT-141 is a melanocortin receptor agonist (MC3R and MC4R) that acts centrally in the hypothalamus to generate sexual desire. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, and it has been used off-label in men for years.

The mechanism is distinct from every other tool in this list. PT-141 does not improve blood flow, does not raise testosterone, and does not reduce prolactin. It triggers dopamine release in the hypothalamic nuclei that control sexual motivation. You take it and you want sex. That is a fundamentally different mechanism than any hormonal intervention.

Pfaus et al. (2022) reviewed the neurobiology in detail: PT-141 activates MC4R receptors in the medial preoptic area and paraventricular nucleus, driving dopaminergic output that initiates sexual motivation (Pfaus et al., 2022). In practice, men describe the effect as desire returning: not just the mechanics improving, but actually wanting it.

Safarinejad and Hosseini (2008) tested PT-141 in men who had failed sildenafil: 33.5% achieved a positive response, compared to 8.5% with placebo (Safarinejad & Hosseini, 2008). That is a meaningful salvage rate in men for whom conventional options had already failed.

Dosing: 1.75 mg subcutaneous injection approximately 45 minutes before anticipated sexual activity. Side effects include transient nausea (the most common complaint), flushing, and transient increases in blood pressure. The nausea is dose-dependent and can be reduced by starting at a lower dose and titrating up. Do not use PT-141 if you are taking antihypertensives, as the blood pressure effect can be additive.

The combination of PT-141 and a PDE5 inhibitor is well-supported. Diamond et al. (2005) demonstrated that PT-141 plus sildenafil produced significantly better outcomes than sildenafil alone (Diamond et al., 2005). For men with both absent desire and impaired mechanics, using both together targets both problems simultaneously.

Cabergoline: the prolactin reset

If your prolactin is elevated above 15 ng/mL, the first intervention is not tadalafil or PT-141. It is prolactin normalization with cabergoline.

Cabergoline is a dopamine agonist (D2 receptor) that suppresses prolactin secretion from the pituitary. Kruger et al. (2003) demonstrated that cabergoline enhanced sexual drive and intensity of orgasm in healthy men through dopaminergic mechanisms (Kruger et al., 2003). In a longer-term study, De Rosa et al. (2004) followed 51 men with hyperprolactinemia-related sexual dysfunction through 6 months of cabergoline therapy: among those who achieved prolactin normalization, 60.6% regained normal nocturnal penile tumescence (De Rosa et al., 2004).

Safarinejad (2006) extended this further: cabergoline worked as a salvage therapy in men with sexual dysfunction who had not responded to PDE5 inhibitors, with 31.2% showing meaningful improvement versus 7.1% on placebo (Safarinejad, 2006). A subset of PDE5i non-responders have underlying hyperprolactinemia as the root cause, and cabergoline addresses that where tadalafil cannot.

Standard dosing: 0.25-0.5 mg twice per week. Start at 0.25 mg to assess tolerance. Common side effects include nausea and dizziness, both of which are generally manageable. At standard doses, the cardiac valve concerns associated with Parkinson's doses (3-4 mg/day) are not relevant.

Cabergoline is worth using after nandrolone or trenbolone cycles. If you have run 19-nor compounds and your libido has not recovered months after stopping, test prolactin before concluding your hormonal recovery is incomplete.

The decision hierarchy

This is how to choose which tool to use:

1. Prolactin elevated above 15 ng/mL: cabergoline first. Get prolactin into range before adding anything else.
2. Desire absent, mechanics reasonable: PT-141. The desire problem is central (dopaminergic), not vascular.
3. Mechanics failing, desire present: tadalafil 5 mg daily. The problem is vascular/erectile, not motivational.
4. Both desire and mechanics impaired, hormones optimized: PT-141 plus tadalafil together.

Layer 3: the dopamine problem nobody talks about

You can have perfect free testosterone, E2 at 25 pg/mL, prolactin at 8 ng/mL, normal thyroid, no 5-ARI use, and still have absent or severely diminished libido. This is Layer 3, and it is where most TRT troubleshooting guides stop, because the solutions require behavioral change rather than prescriptions.

Pornography, novelty, and reward circuit conditioning

The sexual reward system runs on novelty and unpredictability. This is the same dopaminergic mechanism that drives any habit: the brain releases dopamine in anticipation of a novel reward, not a predictable one.

Brand et al. (2016) demonstrated using fMRI that men with compulsive pornography use showed increased ventral striatum activation in response to pornographic cues, a pattern consistent with reward-pathway sensitisation seen in other addictive behaviours (Brand et al., 2016). The striatum becomes calibrated to a level of novelty and visual intensity that a real partner cannot match.

Jacobs et al. (2021) found that 21% of men aged 18-35 reported erectile dysfunction, and problematic pornography use was significantly correlated with this rate (Jacobs et al., 2021). This is a striking number in a demographic that should have robust erectile function.

The nuance matters here: Grubbs and Gola (2019) found that casual pornography use in itself was not correlated with sexual dysfunction (Grubbs & Gola, 2019). The association appeared with escalation, with seeking increasingly extreme content to achieve the same level of arousal, which is the behavioural definition of tolerance. Casual use is not the issue. Escalation is.

Frame this mechanistically, not morally. If you have trained your dopamine system to respond to a specific intensity of novel visual stimulation, the same system will produce reduced arousal in response to a real partner in a familiar context. No hormone optimizes this. The solution is reducing or eliminating pornography use to allow the reward threshold to recalibrate. The timeline is typically 60-90 days for meaningful improvement, consistent with the time required for dopamine receptor density changes.

Performance anxiety: the self-reinforcing loop

Performance anxiety affects an estimated 9-25% of men and is especially common in men who have had a single episode of erectile failure, even if the initial failure had a clear organic cause (Pyke, 2020).

The mechanism is a feedback loop. An erection fails once. The next encounter begins with anticipatory anxiety, which activates the sympathetic nervous system. Sympathetic activation causes vasoconstriction in the penile vasculature. The erection is impaired or absent. This confirms the fear, which increases anxiety in subsequent encounters. The cycle sustains itself.

The psychiatric term for the cognitive mechanism is "spectatoring": mentally observing yourself during sex rather than being present in the experience. It is the sexual equivalent of thinking about your running form mid-race. The monitoring itself impairs performance.

Short-term PDE5 inhibitors serve a useful purpose here beyond their vascular mechanism. By reliably producing erections, they break the anxiety cycle and allow you to experience successful encounters, which rewires the association between sex and failure. Once confidence returns over several weeks, many men can taper off the medication and maintain function. This is tadalafil used as a behavioral reconditioning tool, not just a vascular drug.

Sleep apnoea: the organic cause hiding in plain sight

Obstructive sleep apnoea is highly prevalent in the TRT demographic (middle-aged men, higher body mass, often greater neck circumference from muscle mass) and is one of the most commonly missed organic causes of both low libido and erectile dysfunction.

Soukhova-O'Hare et al. (2008) demonstrated in an animal model that chronic intermittent hypoxia (the mechanism of OSA) reduced spontaneous erections by 55%, independent of testosterone levels (Soukhova-O'Hare et al., 2008). The mechanism is vascular: chronic hypoxia damages the nitric oxide-producing endothelium in penile tissue. Hart et al. (2021) found that in a urology clinic population, every man who completed a home sleep test was diagnosed with OSA, and 44% of the broader referral group already carried a testosterone deficiency diagnosis (Hart et al., 2021). The overlap between low T and undiagnosed OSA is enormous.

If you snore, wake unrefreshed, have a collar size above 43 cm, or have been told you stop breathing at night, screen for OSA before blaming your TRT protocol. Use the STOP-BANG questionnaire (Snoring, Tired, Observed apnoea, Pressure hypertension, BMI over 35, Age over 50, Neck circumference, male Gender): a score of 3 or more warrants a sleep study.

OSA matters beyond libido. It raises cortisol, disrupts testosterone's nocturnal secretion pattern (even on TRT, endogenous pulsatility contributes), impairs sleep quality, and increases cardiovascular risk. Treatment with CPAP can meaningfully improve erectile function independently of hormone levels.

Relationship habituation and the Coolidge effect

The final layer is also the most frequently denied. Human sexual desire is powerfully influenced by novelty, and long-term relationships reduce novelty by definition.

Morton and Gorzalka (2015) documented the arousal decrease that occurs with partner familiarity: desire declines in long-term relationships in a pattern consistent across multiple studies, independent of hormonal changes (Morton & Gorzalka, 2015). Ventura-Aquino et al. (2018) showed that motivational decline with a familiar partner occurs at a neurological level, distinct from the capacity for arousal, which itself remains intact (Ventura-Aquino et al., 2018). This is the Coolidge effect: the same biological drive for novelty that exists in other mammals.

This is not a hormonal problem. No testosterone dose fixes relationship habituation. The approaches that actually work are non-pharmacological: introducing context novelty (new environments, timing, scenarios), addressing emotional disconnection as its own problem, and in some cases working with a sex therapist. The mechanical tools (tadalafil, PT-141) will improve the mechanics of encounters, but they will not restore the motivational component that comes from genuine desire for a partner.

The practical point: if your libido is completely normal during travel, when you encounter an attractive stranger, or when fantasizing, but absent in the context of your primary relationship, your hormones are almost certainly not the problem. The panel is not going to tell you anything actionable. Layer 3 is where you need to look.

The libido troubleshooting panel

This is the complete panel for a systematic workup. Draw at trough (24-48 hours post-injection for testosterone esters).

Note on DHT testing: it is not available in all labs and the reference range varies considerably between assays. Prioritise if you use finasteride or dutasteride. Otherwise, it is a secondary marker.

Note on LH and FSH: on exogenous testosterone, both will be suppressed to near-zero and tell you nothing useful. Do not order them unless you are off TRT and assessing recovery or investigating primary versus secondary hypogonadism. For context on HCG and fertility monitoring, LH analogues become relevant again.

Putting it together: the step-by-step protocol

Step 1: Get the full panel. Order the complete panel above: free testosterone, SHBG, sensitive estradiol, prolactin, TSH, free T3, free T4, and morning cortisol. If you use a 5-ARI, add DHT. Draw at trough, fasted, morning.

Step 2: Fix the hormonal layer first. Work through the markers in priority order:

• Free T low: address SHBG root cause or optimize injection frequency and dose. For context on when and how to draw blood on TRT, timing matters here.
• E2 out of range: adjust AI dose (low E2 means less AI, not more testosterone; high E2 means less testosterone or minimum effective AI dose).
• Prolactin above 15: start cabergoline 0.25 mg twice weekly and retest in 6 weeks.
• Thyroid abnormal: address with a GP. Subclinical hypothyroidism is often treated when symptomatic.
• Cortisol dysregulated: identify the stressor (overtraining, caloric deficit, life stress) and address directly.

Do not add pharmacological tools (Layer 2) until you have given the hormonal corrections 6-8 weeks to take effect. Hormonal changes take time. Adding PT-141 on top of unresolved hyperprolactinemia wastes money and muddies the picture.

Step 3: Add pharmacological tools if hormones are optimized. If all markers are in optimal ranges and libido remains impaired after 6-8 weeks:

• Desire absent, mechanics reasonable: try PT-141 1.75 mg SubQ 45 minutes before anticipated activity. Assess over 4-6 uses.
• Mechanics impaired, desire present: tadalafil 5 mg daily for 4 weeks. Assess erectile quality.
• Both impaired: combine tadalafil daily and PT-141 on-demand.

Step 4: Address Layer 3. Regardless of hormonal status:

• Audit pornography use honestly. If frequency is high or content has escalated, implement a structured abstinence period of at least 60 days and reassess.
• Screen for OSA using STOP-BANG. Score 3+: refer for a sleep study.
• Consider whether performance anxiety is driving a feedback loop. Short-term tadalafil can break the cycle.
• Assess relationship context honestly. If libido is context-specific rather than globally absent, the hormonal panel will not find an answer.

Step 5: Retest in 6-8 weeks. After any intervention, retest the relevant markers at trough. Prolactin should normalize within 4-6 weeks on cabergoline. Estradiol changes are visible within 2-4 weeks. Free T changes require 4-6 weeks of stable dosing before drawing conclusions. Do not chase single data points. Two consecutive trough values are more reliable than one.

Key takeaways

• Total testosterone tells you almost nothing about libido. Free testosterone is the marker that matters. Men with normal total T but low free T below 220 pmol/L remain symptomatic.
• Estradiol has a sweet spot for libido: 20-30 pg/mL on a sensitive assay. Both low E2 (the more common clinical error) and high E2 above 42-45 pg/mL impair sexual function. Low E2 kills desire. Crashing it with AIs is one of the most common causes of TRT-era libido loss.
• Prolactin above 15 ng/mL can suppress libido with completely normal testosterone. It is especially common with 19-nor compound use and is fixable with cabergoline. It is one of the most under-tested markers in TRT management.
• Hypothyroidism delivers a double hit: it reduces dopaminergic tone directly and raises SHBG, suppressing free testosterone. Test TSH, free T3, and free T4, not TSH alone.
• DHT matters for desire independent of estradiol. 5-alpha reductase inhibitors for hair loss can suppress libido as a primary side effect. Weigh the trade-off explicitly.
• Tadalafil fixes mechanics, not desire. PT-141 (bremelanotide) fixes desire via central MC4R/dopamine mechanisms. They target different problems and can be combined.
• Cabergoline is the first tool when prolactin is elevated, before tadalafil or PT-141. Fixing the root cause is always preferable to masking symptoms with additional agents.
• Performance anxiety creates a self-sustaining loop. Short-term PDE5 inhibitor use can break the cycle through behavioral reconditioning, not just vascular effects.
• Sleep apnoea is highly prevalent in the TRT demographic and independently damages erectile function through endothelial hypoxic injury. STOP-BANG screen everyone with symptoms.
• Relationship habituation is a neurological phenomenon, not a hormonal one. No dose adjustment fixes it. Novelty, emotional connection, and sometimes professional support are the actual levers.

References

Antonio, L., Wu, F. C. W., O'Neill, T. W., Pye, S. R., Carter, E. L., Finn, J. D., ... & Vanderschueren, D. (2016). Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. Journal of Clinical Endocrinology and Metabolism, 101(7), 2647-2657. https://pubmed.ncbi.nlm.nih.gov/26909800/

Belladelli, F., Basran, S., Muncey, W., Diaz, M. Q., Manatakis, D., Del Giudice, F., Eisenberg, M. L., & Pozza, C. (2024). The association between estradiol levels and erectile dysfunction. Endocrine, 83(1), 79-84. https://pubmed.ncbi.nlm.nih.gov/37261881/

Brand, M., Snagowski, J., Laier, C., & Maderwald, S. (2016). Ventral striatum activity when watching preferred pornographic pictures is correlated with symptoms of Internet pornography addiction. NeuroImage, 129, 224-232. https://pubmed.ncbi.nlm.nih.gov/26803060/

Buvat, J., Montorsi, F., Maggi, M., Porst, H., Kaipia, A., Colson, M. H., & Cunningham, G. R. (2011). Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine, 8(1), 284-293. https://pubmed.ncbi.nlm.nih.gov/20704642/

Carani, C., Isidori, A. M., Granata, A., Carosa, E., Maggi, M., Lenzi, A., & Jannini, E. A. (2005). Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. Journal of Clinical Endocrinology and Metabolism, 90(12), 6472-6479. https://pubmed.ncbi.nlm.nih.gov/16204360/

Cheng, X., Xiao, Y., Deng, Y., Chen, Q., Wen, X., Zhou, E., & Zhou, H. (2025). Idiopathic hyperprolactinemia-associated hypogonadism in men presenting with normal testosterone levels. PLoS One. https://pubmed.ncbi.nlm.nih.gov/40966237/

Cumming, D. C., Quigley, M. E., & Yen, S. S. (1983). Acute suppression of circulating testosterone levels by cortisol in men. Journal of Clinical Endocrinology and Metabolism, 57(3), 671-673. https://pubmed.ncbi.nlm.nih.gov/6348068/

De Rosa, M., Zarrilli, S., Vitale, G., Di Somma, C., Orio, F., Tauchmanova, L., Lombardi, G., & Colao, A. (2004). Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: An open longitudinal study monitoring nocturnal penile tumescence. Journal of Clinical Endocrinology and Metabolism, 89(2), 621-625. https://pubmed.ncbi.nlm.nih.gov/14764772/

Diamond, L. E., Earle, D. C., Rosen, R. C., Wilber, M. S., & Molinoff, P. B. (2005). Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology, 65(4), 755-759. https://pubmed.ncbi.nlm.nih.gov/15833522/

Falaschi, P., Rocco, A., Migliaresi, S., & Frajese, G. (1978). Sexual disturbances in hyperprolactinaemic patients with normal testosterone. Journal of Endocrinological Investigation, 1(4), 297-302. https://pubmed.ncbi.nlm.nih.gov/647993/

Finkelstein, J. S., Lee, H., Burnett-Bowie, S. A. M., Pallais, J. C., Yu, E. W., Borges, L. F., Jones, B. F., Barry, C. V., Wulczyn, K. E., Thomas, B. J., & Leder, B. Z. (2013). Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine, 369(11), 1011-1022. https://pubmed.ncbi.nlm.nih.gov/24024838/

Gabrielson, A. T., Sartor, R. A., & Hellstrom, W. J. G. (2019). The impact of thyroid disease on sexual dysfunction in men and women. Sexual Medicine Reviews, 7(1), 57-70. https://pubmed.ncbi.nlm.nih.gov/30057137/

Grubbs, J. B., & Gola, M. (2019). Is pornography use related to erectile functioning? Results from cross-sectional and latent growth curve analyses. Journal of Sexual Medicine, 16(1), 111-125. https://pubmed.ncbi.nlm.nih.gov/30621919/

Hart, M., et al. (2021). Identifying signs and symptoms of obstructive sleep apnea in a men's health clinic. American Journal of Men's Health, 15(4). https://pubmed.ncbi.nlm.nih.gov/34190623/

Jacobs, T., Geysemans, B., Van Hal, G., Glazemakers, I., Fog-Poulsen, K., Vermandel, A., De Wachter, S., & De Win, G. (2021). Associations between online pornography consumption and sexual dysfunction in young men: Multivariate analysis based on an international web-based survey. JMIR Public Health and Surveillance, 7(10), e32542. https://pubmed.ncbi.nlm.nih.gov/34534092/

Kruger, T. H. C., Haake, P., Hartmann, U., Schedlowski, M., & Exton, M. S. (2003). Orgasm-induced prolactin secretion: Feedback control of sexual drive? Neuroscience and Biobehavioral Reviews, 27(1-2), 31-44. https://pubmed.ncbi.nlm.nih.gov/14656205/

Morton, H., & Gorzalka, B. B. (2015). Role of partner novelty in sexual functioning: A review. Journal of Sex and Marital Therapy, 41(6), 593-609. https://pubmed.ncbi.nlm.nih.gov/25222339/

Pencina, K. M., Lincoff, A. M., Nissen, S. E., Li, Z. B., Chevli, P., Snyder, P. J., Bhasin, S., & TRAVERSE Study Research Group. (2024). Testosterone and sexual function outcomes in men with hypogonadism. Journal of Clinical Endocrinology and Metabolism, 109(3), 725-732. https://pubmed.ncbi.nlm.nih.gov/37589949/

Pfaus, J. G., Sadiq, A., Spana, C., & Clayton, A. H. (2022). The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectrums, 27(3), 281-289. https://pubmed.ncbi.nlm.nih.gov/33455598/

Porst, H., Oelke, M., Goldfischer, E. R., Cox, D., Watts, S., & Elion-Mboussa, A. (2014). Efficacy and safety of tadalafil 5 mg once daily in men with erectile dysfunction: An integrated analysis of data obtained from 1,913 patients from six randomized, double-blind, placebo-controlled clinical studies. European Urology, 65(3), 455-464. https://pubmed.ncbi.nlm.nih.gov/24119319/

Pyke, R. E. (2020). Sexual performance anxiety. Sexual Medicine Reviews, 8(2), 183-190. https://pubmed.ncbi.nlm.nih.gov/31447414/

Rosano, G. M. C., Aversa, A., Vitale, C., Fabbri, A., Fini, M., & Spera, G. (2005). Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. European Urology, 47(2), 214-220. https://pubmed.ncbi.nlm.nih.gov/15661417/

Safarinejad, M. R. (2006). Salvage of sildenafil failures with cabergoline: A randomized, double-blind, placebo-controlled study. International Journal of Impotence Research, 18(6), 550-558. https://pubmed.ncbi.nlm.nih.gov/16625231/

Safarinejad, M. R., & Hosseini, S. Y. (2008). Salvage of sildenafil failures with bremelanotide: A randomized, double-blind, placebo controlled study. Journal of Urology, 179(3), 1066-1071. https://pubmed.ncbi.nlm.nih.gov/18206919/

Sartorius, G. A., Ly, L. P., & Handelsman, D. J. (2014). Male sexual function can be maintained without aromatization: Randomized placebo-controlled trial of dihydrotestosterone (DHT) in healthy, older men for 24 months. Journal of Sexual Medicine, 11(10), 2562-2570. https://pubmed.ncbi.nlm.nih.gov/24751323/

Soukhova-O'Hare, G. K., Shukla, R., & Gozal, D. (2008). Erectile dysfunction in a murine model of sleep apnea. American Journal of Respiratory and Critical Care Medicine, 178(6), 644-650. https://pubmed.ncbi.nlm.nih.gov/18535258/

Traish, A. M., Mulgaonkar, A., & Giordano, N. (2014). The dark side of 5alpha-reductase inhibitors' therapy: Sexual dysfunction, high Gleason grade prostate cancer and depression. Korean Journal of Urology, 55(6), 367-379. https://pubmed.ncbi.nlm.nih.gov/24955220/

Ventura-Aquino, E., Fernandez-Guasti, A., & Paredes, R. G. (2018). Hormones and the Coolidge effect. Molecular and Cellular Endocrinology, 467, 42-48. https://pubmed.ncbi.nlm.nih.gov/28912031/